1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Hemorrhage - Pipeline Review, H1 2015

Hemorrhage - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 41 pages

Hemorrhage - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Hemorrhage - Pipeline Review, H1 2015’, provides an overview of the Hemorrhage’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemorrhage
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hemorrhage and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hemorrhage pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hemorrhage
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hemorrhage - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Hemorrhage Overview 6
Therapeutics Development 7
Pipeline Products for Hemorrhage - Overview 7
Pipeline Products for Hemorrhage - Comparative Analysis 8
Hemorrhage - Therapeutics under Development by Companies 9
Hemorrhage - Therapeutics under Investigation by Universities/Institutes 10
Hemorrhage - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hemorrhage - Products under Development by Companies 13
Hemorrhage - Products under Investigation by Universities/Institutes 14
Hemorrhage - Companies Involved in Therapeutics Development 15
Cellphire, Inc. 15
Digna Biotech, S.L. 16
Haemostatix Ltd 17
QRxPharma Limited 18
Serendex Pharmaceuticals A/S 19
Thrombotargets Corporation 20
Hemorrhage - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
DB-055 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
eptacog alfa - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
PeproStat - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Q-8008 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Thrombosomes - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
TT-111 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
TT-112 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
V-0801 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Hemorrhage - Recent Pipeline Updates 38
Hemorrhage - Dormant Projects 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables

Number of Products under Development for Hemorrhage, H1 2015 7
Number of Products under Development for Hemorrhage - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Hemorrhage - Pipeline by Cellphire, Inc., H1 2015 15
Hemorrhage - Pipeline by Digna Biotech, S.L., H1 2015 16
Hemorrhage - Pipeline by Haemostatix Ltd, H1 2015 17
Hemorrhage - Pipeline by QRxPharma Limited, H1 2015 18
Hemorrhage - Pipeline by Serendex Pharmaceuticals A/S, H1 2015 19
Hemorrhage - Pipeline by Thrombotargets Corporation, H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Hemorrhage Therapeutics - Recent Pipeline Updates, H1 2015 38
Hemorrhage - Dormant Projects, H1 2015 39

List of Figures

Number of Products under Development for Hemorrhage, H1 2015 7
Number of Products under Development for Hemorrhage - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% during the forecast period. In this report, the bioinformatics ...

Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016

Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • October 2016
  • by Global Data

Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016" ...

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • September 2016
  • by Global Data

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.